Author:
Das Shampa,Riccobene Todd,Carrothers Timothy J.,Wright James G.,MacPherson Merran,Cristinacce Andrew,McFadyen Lynn,Xie Rujia,Luckey Alison,Raber Susan
Abstract
Abstract
Purpose
A series of iterative population pharmacokinetic (PK) modeling and probability of target attainment (PTA) analyses based on emerging data supported dose selection for aztreonam-avibactam, an investigational combination antibiotic for serious Gram-negative bacterial infections.
Methods
Two iterations of PK models built from avibactam data in infected patients and aztreonam data in healthy subjects with “patient-like” assumptions were used in joint PTA analyses (primary target: aztreonam 60% fT > 8 mg/L, avibactam 50% fT > 2.5 mg/L) exploring patient variability, infusion durations, and adjustments for moderate (estimated creatinine clearance [CrCL] > 30 to ≤ 50 mL/min) and severe renal impairment (> 15 to ≤ 30 mL/min). Achievement of > 90% joint PTA and the impact of differential renal clearance were considerations in dose selection.
Results
Iteration 1 simulations for Phase I/IIa dose selection/modification demonstrated that 3-h and continuous infusions provide comparable PTA; avibactam dose drives joint PTA within clinically relevant exposure targets; and loading doses support more rapid joint target attainment. An aztreonam/avibactam 500/137 mg 30-min loading dose and 1500/410 mg 3-h maintenance infusions q6h were selected for further evaluation. Iteration 2 simulations using expanded PK models supported an alteration to the regimen (500/167 mg loading; 1500/500 mg q6h maintenance 3-h infusions for CrCL > 50 mL/min) and selection of doses for renal impairment for Phase IIa/III clinical studies.
Conclusion
A loading dose plus 3-h maintenance infusions of aztreonam-avibactam in a 3:1 fixed ratio q6h optimizes joint PTA. These analyses supported dose selection for the aztreonam-avibactam Phase III clinical program. Clinical trial registration: NCT01689207; NCT02655419; NCT03329092; NCT03580044.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference55 articles.
1. Mojica MF, Rossi MA, Vila AJ, Bonomo RA (2022) The urgent need for metallo-beta-lactamase inhibitors: an unattended global threat. Lancet Infect Dis 22:e28–e34. https://doi.org/10.1016/S1473-3099(20)30868-9
2. Bush K, Bradford PA (2020) Epidemiology of beta-lactamase-producing pathogens. Clin Microbiol Rev 33:e00047-e119. https://doi.org/10.1128/CMR.00047-19
3. Centers for Disease Control and Prevention (2019) Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 10 Jun 2021
4. Karaiskos I, Galani I, Souli M, Giamarellou H (2019) Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol 15:133–149. https://doi.org/10.1080/17425255.2019.1563071
5. Das S, Li J, Riccobene T, Carrothers TJ, Newell P, Melnick D, Critchley IA, Stone GG, Nichols WW (2019) Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia. Antimicrob Agents Chemother 63:e02187-e12118. https://doi.org/10.1128/AAC.02187-18